INTRODUCTION
Retroviral vectors are widely used gene transfer vehicles, which offer the possibility of long-term expression of foreign genes in biomedical research and gene therapy. Nevertheless, their application is also associated with the risk of malignant transformation, 1 as occasionally observed in a number of clinical gene therapy trials. [2] [3] [4] Side effects are caused by the integration of the vector genome into the target cell chromatin and subsequent deregulation of neighboring genes. To prevent insertional mutagenesis, introduction of a missense mutation into the DDE catalytic triad of retroviral integrase can be used reducing integration frequencies by 100-to 1000-fold. 5 After reverse transcription of the RNA genome into double-stranded DNA, the linear DNA precursor is therefore not integrated but preferentially processed into extrachromosomal circular DNA episomes with 1-and 2-long terminal repeats (LTRs). These plasmid-like structures support transient transgene expression, although to a lower extent than their integrated counterparts. 5 Different retroviral genera have been successfully used for retroviral episome transfer (RET), including γ-retroviral (GV), foamy virus-derived and lentiviral (LV) vectors. [6] [7] [8] As retroviral episomes lack an origin of replication (ori), their persistence is inversely dependent on the replication of target cells. 9 Thus, integrationdefective LV vectors are most commonly used as they are capable of transducing quiescent cells, leading to stable gene expression in these postmitotic tissues while avoiding the risks associated with integration. To act in a transient manner in dividing cells, retroviral episomes have been used to express antigens for vaccination purposes, to deliver templates or proteins required for recombination or transposition, to express short hairpin RNAs or to mediate transient gene expression. 5 Owing to the short nature of expression post episomal transfer in dividing cells and the high degree of biosafety, this technology would be ideal for applications with translational prospects requiring temporally restricted expression of transgenes. Regarding natural biologic processes, such profiles of very short expression windows are characteristic for transcription factorbased stimuli. Short pulses of transcription factor expression guide through developmental processes, activating and coordinating cell fate decisions. 10 Importantly, cell fate conversions can be enforced in a targeted manner by ectopic expression of distinct sets of transcription factors. 11 This procedure enables the generation of rare, difficult-to-access or patient-specific cell types. Transient delivery technologies for transcription factors avoiding permanent genetic modification of target cells are thus not only sufficient for conversion but also valuable in the scope of future clinical application.
Conversions successfully accomplished so far can be allocated into one of three categories: (1) differentiation to a more committed state, (2) trans-differentiation of distinct cell types into others within or also across lineages, such as conversion of fibroblasts into muscle cells 12 or of pre-B cells into macrophages, 13 and (3) reversion to a more immature state, including stem cells and, most prominently, reprogramming to pluripotency. Reprogramming to induced pluripotent stem cells (iPSCs) is a well-studied and most demanding system that requires exogenous expression of transcription factors for a relatively long period of time. Starting from fibroblasts, reprogramming can be achieved with a cocktail of four transcription factors, either Oct4, Sox2, Klf4 and c-Myc or, alternatively, Oct4, Sox2, Nanog and Lin28. [14] [15] [16] Conversion usually requires expression of these factors for at least 8-10 days in human cells. 17 Using cell types other than fibroblasts or by administering certain small-molecule inhibitors, individual factors can be omitted from the cocktail, with the exception of Oct4, which is required for almost all reprogramming settings and which also is one of the endogenous key factors maintaining the pluripotent network. 18, 19 Beyond its role in reprogramming and pluripotency, Oct4 overexpression was reported to support a number of further conversion scenarios, including the generation of neural progenitors, 20 neural stem cells, 21 multilineage blood progenitors 22 and cardiomyocytes. 23 To achieve cell fate modification without permanent genetic modification of target cells, we established and improved transient, episomal delivery of transcription factors using RET, exemplarily for the delivery of the prototypical cell fate influencing transcription factor Oct4. We aimed to improve episomal expression by identifying the optimal vector design for RET among different retroviral vector genera and architectures, and by exploring the potential benefit of epigenetic modifiers. Proteotuning of the model transcription factor Oct4 was investigated as a further means to enhance overall efficiency. To enlarge episomal expression windows, the option of repeated transductions was tested in kinetic experiments, and detailed recording of the course of expression after a single round of transduction was performed to identify optimal time points for repeated administration. As a proof-of-principle for the applicability of RET for cell fate conversion, reprogramming of human fibroblasts to iPSCs was attempted. While it was not our goal to improve reprogramming methodologies, we consider the generation of iPSCs with the requirement for a comparably long and sustained transgene expression as a challenging and thus most convincing application scenario for an improved RET system.
RESULTS

Retroviral vector characteristics affecting episome transfer efficiency
To identify the most versatile retroviral vector system for the transient delivery of transcription factors, we compared different retroviral vector genera and architectures for RET. Oct4 was selected as a protein of choice because of its pleiotropic applicability and pivotal role in several cell fate conversion processes. To achieve high expression levels, the potent retroviral spleen focus-forming virus (SFFV) U3 promoter was used to drive a codon-optimized human Oct4 (hOct4co) sequence, and also a post-transcriptional regulatory element (PRE) was included in all vector designs. 24 A transient dual-luciferase reporter assay system was established to quantify transfer and activity of ectopic hOct4co. Episomal titers were assessed by quantitative PCR detecting the codon-optimized Oct4 sequence and used to normalize luciferase assay counts to determine episomal expression per single vector copy.
Cell fate conversions are often accomplished using dividing cell sources, so that delivery vehicles within the retroviral family are not restricted to those genera that are capable of transducing quiescent cells. As GV and LV vectors are the best-characterized and most commonly used retroviral vector types, we compared these for their efficiency of episomal (e) hOct4co transfer and expression. For both genera, a self-inactivating (SIN) vector architecture lacking the viral promoter and enhancer elements residing within the LTRs, replaced by an internal SFFV promoter, was used to express the transgene (Figure 1a) . Quantitative PCR analysis demonstrated successful episome production using the D184A integrase mutation for eGV and the D64V mutation for eLV vector production ( Supplementary Figures S1a and b) . Comparison for hOct4co transfer efficiencies in luciferase assays revealed eGV vectors to be more potent per single copy than eLV vectors; however, the difference was not significant with lower amounts (5 μl) of supernatant ( Figure 1b) . Additionally favoring the use of GV vectors for RET, these yielded higher titers as compared with LV episome preparations ( Supplementary Figures S1a and b) .
Two basic configurations are possible for retroviral vector architectures: the SIN design and LTR-driven vectors using viral promoter and enhancer elements present within the LTRs. Therefore, SIN and LTR-driven designs were compared within the GV background. The SFFV promoter was also chosen for the LTR-driven vectors, residing here within the U3 region. While levels of episomal titers for generated vector preparations were comparable when using the SIN architecture ( Supplementary  Figures S1c and d) , expression of hOct4co by the LTRs was 2-to 3.5-fold more efficient per transduced vector copy than with the corresponding SIN architecture ( Figure 1c) .
As many cell fate conversion processes require the action of more than one transcription factor, we explored the possibility of expressing long transgene cassettes from RET constructs. Exemplified for a reprogramming context, polycistronic cassettes encoding two reprogramming factors (hOct4co and hKlf4co = OK) or all four reprogramming factors (hOct4co, hKlf4co, hSox2co and hc-Myc = OKSM) separated by heterologous 2A protease cleavage sites were generated ( Figure 1a) . Quantification of episomal copy numbers in generated vector preparations revealed the possibility to obtain high titers even with the long OKSM cassette (Supplementary Figures S1e and f) . Determination of Oct4 reporter activation using the luciferase assay system after transfer of the three different cassettes by eGV LTR-driven vectors showed reporter activation above the levels of non-transduced control cells in all cases, indicating that co-delivery of several transgenes by retroviral episomes is possible (Figure 1d ). However, transfer efficiency of hOct4co decreased with an increasing number of transgenes co-expressed from the same vector, with 430-40-fold higher transactivation levels per vector copy for the Oct4-expressing vector as compared with the OKSM-transferring counterpart (Figure 1d ). Thus, RET efficiency seems to be dependent on the length of the transgene cassette, and a GV LTR-driven vector design encoding a single transgene appeared most efficient in delivering hOct4co using RET.
Valproic acid increases expression from retroviral episomes Cell fate conversion processes generally require high expression levels of defined transcription factors. Having determined an optimal vector configuration for the transient expression of hOct4co, we next sought to further increase episomal expression as it is known to be weaker than the expression from integrating vectors. 5 An hOct4co-eGFP fusion protein was generated to track expression levels by the mean fluorescence intensity of eGFP (Supplementary Figure S2a) . Following transduction into HeLa P1 cells by an eGV SIN vector, the chimeric protein localized to the nucleus (Supplementary Figure S2b) and transactivated the Oct4 luciferase reporter system, albeit at lower levels as compared with unmodified hOct4co (Supplementary Figure S2c) . Retroviral vector titers were assessed by quantitative PCR (Supplementary Figure S2d) .
Histone deacetylase inhibitors (HDACi) interfere with the removal of acetylation marks on histone tails, thereby relaxing chromatin structures and counteracting silencing. Previous reports have shown that the use of HDACi elevates episomal transgene expression from GV and LV vectors. 25 ,26 Therefore, we tested the HDACi valproic acid (VPA) in our experimental setting. Flow cytometric analyses revealed that VPA improved expression of the hOct4co-eGFP fusion protein by 1.5-fold in human neonatal foreskin fibroblasts (NuFFs) (Figure 2a ) and more than 2.5-fold in 293T cells (Figure 2b) , both when using SIN or LTR-driven eGV vectors.
Fusion to a minimal transactivation motif of VP16 enhances Oct4 performance In addition to enhancement of transgene expression by optimized vector architecture and chromatin configuration, optimization of the transgene itself may also improve expression and performance. Transactivation capacity of transcription factors can be increased by heterologous transactivation domains (TAD). The herpes simplex virus (HSV) viral protein 16 (VP16) is one of the most potent transactivators described. As VP16 is known to be cytotoxic, 27, 28 we used a threefold minimal motif repeat of VP16's acidic TAD that yields similar transactivation effects as the full TAD. 29, 30 Fusion of this triple minimal motif to the C-terminus of hOct4co, interspaced by a short linker (Figure 2c ), more than doubled the activity of the chimeric protein (Oct4-VP16) in the luciferase reporter system following transfer by an LTR-driven eGV vector (Figure 2d ), whereas titers of generated vector preparations were comparable (Supplementary Figures S2e and f) .
Overall, efficiency of the episomal Oct4 transfer system was improved by elevating episomal expression levels using VPA and more specifically by increasing the transactivation capacity of Oct4 via fusion to a strong transactivation motif originating from HSV VP16.
Repeated episomal transductions generate a stable percentage of transgene-expressing cells and stable expression levels over a defined time period Apart from high expression levels, cell fate conversions often require expression of the respective transcription factors for a certain period of time. To investigate transgene expression kinetics upon episomal transfer, 293T cells were transduced once with GV LTR-driven or SIN vectors encoding destabilized GFP (d2GFP), which exhibits a half-life (2 h) comparable to murine Oct4 (~90 min). 31 The percentage of positive cells as well as the expression from episomes peaked at 36 h after a single round of transduction and d2GFP transgene expression was undetectable after 72 h, whereas control integrating vectors exhibited stable expression levels (Figures 3a and b) . As this time window is too short for many conversions, we hypothesized that repeated rounds of transduction would create a stable number of transgene-expressing cells. Indeed, repeated exposure of 293T cells in 24 h intervals with LTR-driven or SIN eGV vectors expressing d2GFP resulted in the generation of a temporarily stable fraction of transgene-positive cells and stable mean expression levels (Figures 3c and d) . In contrast to stable long-term expression by integrating vectors, episomal transgene expression declined to baseline within 36 h after cessation of transductions.
To assess directly the kinetics of Oct4 transfer in a functional assay, we established a stable 293T Oct4 luciferase reporter cell line (Supplementary Figure S3a) . Again, after a single episomal Repeated episomal transduction is efficient and non-toxic in primary cells Although transient DNA delivery modes already exist, most commonly based on plasmid transfection or electroporation, there is still a requirement for alternative strategies, especially as primary cells can be refractory to transfection and the required agents might be cytotoxic. In contrast, viruses have adapted to be highly efficient in accessing primary cells without causing extensive damage. We thus directly compared the RET technology to standard plasmid transfer protocols and determined both efficiency and toxicity after single and repeated (three times on consecutive days) transfer of d2GFP. Whereas episomal transduction showed comparable efficiencies to polyethylenimine-or Lipofectamine-based transfection in 293T cells, it was superior in accessing human fibroblasts (NuFFs) (Supplementary Figures S4i and j). Furthermore, transduction showed comparable toxicity to these transfection modes after single application and even higher Figures S4i and j) . However, nucleofection was inferior to episomal transduction ( Supplementary Figures S4i and j) , and was associated with substantial toxicity (Supplementary Figures S4a-h) . Altogether, RET allowed increased gene transfer efficiencies in NuFF cells as compared with transfection or nucleofection, and cell toxicity due to RET was comparable to or even lower than that observed for the other methods.
hiPSCs generated by episomal transfer of Oct4-VP16 To demonstrate a biologic effect of transcription factor delivery using the RET technology, a proof-of-principle reprogramming experiment was performed using NuFFs. The aim was not to develop an improved reprogramming technique, but it was chosen to demonstrate the potency of RET-mediated delivery of transcription factors. We delivered our model transcription factor Oct4 using episomal vector preparations, and supplied hKlf4co, hSox2co and hc-Myc in trans by stable integration using a polycistronic iLV vector (LV KSM) (Figures 4a and b) . To integrate the improvements of episomal Oct4 transfer, an LTR-driven eGV vector was combined with the optimized Oct4-VP16 fusion (GV Oct4-VP16), and VPA was added during reprogramming to amplify episomal expression levels. Furthermore, based on our kinetic analyses, the episomal vector was repeatedly applied in 24 or 48 h intervals (Supplementary Figures S5a and b) . hiPSCs were reproducibly obtained in two independent reprogramming approaches, with efficiencies of 0.02-0.04% (Reprogramming 1) and 0.07-3.5% (Reprogramming 2) (Supplementary Figure S5c) . In contrast to Oct4-VP16, unmodified hOct4co included in one of the reprogramming approaches did not trigger the emergence of hiPSCs.
Low residual integration frequencies of episomal vector in hiPSCs Independent of the preclusion of specific retroviral integration by mutation of the viral integrase, episomal vectors may spontaneously integrate into the target cell genome. Furthermore, the reprogramming process involves high selection pressure, which might favor the emergence of iPSC clones with a highly expressing integrated Oct4 cassette. Thus, hiPSC clones were analyzed for integrations by determining hOct4co copy numbers using quantitative PCR on genomic DNA. In Reprogramming 1 (Supplementary Figure S5a) , primary hiPSC colonies were subcloned as iPSC colonies may represent genetic mosaics that emerge from different clusters during reprogramming. 32 More than 50% of clones generated using our episomal methodology were free of residual integration in two independent reprogramming approaches (Figure 4c hiPSCs fulfill pluripotency criteria Cultures analyzed for residual integrations displayed iPSC morphology for more than 40 passages. The generated hiPSCs were further characterized to demonstrate that our transient RET system is potent enough to achieve full fate conversion. To determine the expression of pluripotency markers in representative clones ( Figure 5 ), we chose two Oct4-VP16-free RET clones (Epi I and Epi VIII) and a control hiPSC clone (Int I) harboring the integrated Oct4-VP16 construct (Supplementary Figure S5e) . At the RNA level, the pluripotency genes Oct4, Nanog and Dnmt3B were expressed at amounts comparable to a reference human embryonic stem cell (hESC) line (H9) 15 ( Figure 5a ). Also using immunocytochemistry, all clones analyzed were positive for the expression of Oct4, a major component of the pluripotency network (Figure 5b ).
Reprogramming vectors have been observed to become silenced during the late steps of reprogramming, marking fully reprogrammed iPSCs as opposed to only partially reprogrammed cells. 32, 33 Quantification of the PRE sequence, a component of all vectors used for reprogramming, in total RNA indicated silencing of the integrated reprogramming components in our hiPSC clones (Figure 5c ).
Flow cytometric analysis of hiPSCs further revealed high expression of the surface pluripotency markers SSEA-3, SSEA-4, TRA-1-60 and TRA-1-81 in all three representative clones (Figure 5d) . Importantly, the genomic integrity of generated hiPSCs was not affected by the episomal approach despite multiple transductions. No major chromosomal aberrations in hiPSC clones Epi I and Int I and only few copy number variations in clone Epi VIII were detected by array comparative genomic hybridization (Supplementary Figure S6) . A single aberration on chromosome 8 was observed in all three hiPSC clones. However, this originated from the parental NuFF cells used as the cell source for reprogramming (Supplementary Figure S6) .
Inspection of scatterplots comparing whole genome profiles demonstrated that the global gene expression profiles from our hiPSC lines resembled PSCs and differed from somatic cells (fibroblasts) (Supplementary Figures S7a-f) . Genes intricately linked with pluripotency (POU5F1 (OCT4), SOX2, NANOG, ZFP42 (REX1), SALL4, LIN28, DNMT3A, GDF3, GRB7 and TDGF1) and commonly used as markers for pluripotent cells 34 were highly upregulated in our hiPSCs when compared with MRC5 fibroblasts (Supplementary Figures S7a-c ) and expressed at comparable levels when compared with H9 hESCs (Supplementary Figures S7d-f) .
To further characterize pluripotent features comprehensively, we applied the PluriTest methodology on whole genome transcription profiles (Figure 5e) . 35 PluriTest is a bioinformatic assay for accurate assessment of pluripotency, which analyzes the expression of a large number of pluripotency-associated transcripts with a 'Pluripotency Score' and tests for the conformity of a given sample with the global transcriptional profile typical for genetically and epigenetically normal hESCs and hiPSCs with a metric termed 'Novelty Score'. The PluriTest assay eliminates the need of animal use for teratoma formation assay. 35 Using this approach, the tested samples from hiPSC clones Epi I, Epi VIII and Int I passed the empirically defined pluripotency and novelty score thresholds and thus closely fit the highly validated, global statistical model for the genome-wide transcriptional landscape of human PSCs (Figure 5e ).
These results provide evidence for the successful reprogramming of human fibroblasts using the RET technology to deliver Oct4-VP16, creating hiPSCs devoid of residual integration that fulfill pluripotency criteria. Thus, our improved RET system allowed sufficient expression and kinetics to enable cell fate conversion using a key transcription factor.
DISCUSSION
Cell fate conversion is mediated by the concerted action of short waves of distinct transcription factors. 10, 11 To mimic the natural pattern and sequence of transcription factor expression and thus modify cell fate in a targeted manner, technologies that enable ectopic transcription factor expression over a defined time and space and in adjustable magnitude appear most suitable.
Inducible promoters match these criteria, allowing temporal restriction of transgene expression. 36 However, their use bears the risk of causing genotoxicity as it involves stable integration into the host cell chromatin. Furthermore, this system requires constitutive expression of a transactivator along with administration of a drug. Owing to leakiness of inducible promoters, transgenes may be residually expressed, potentially interfering with further differentiation of generated cell types. 37 Finally, expression levels cannot be adjusted as precisely as with transient delivery techniques. Requiring only short-term expression of transcription factors during, but not after conversion, transient integration-free techniques appear most suitable within the area of cell fate modification. Several delivery modes have been described already, including also DNA-based and viral approaches. Especially in reprogramming, suitability of transient technologies for successful conversion has been demonstrated. Nevertheless, each system is associated with intrinsic disadvantages despite the proof-of-principle. Therefore, alternative transient approaches are of interest as no consensus regarding the optimal technology has been reached.
Retroviral vectors are among the most commonly used and best-characterized delivery systems. Importantly, these vectors can be converted into transient vehicles by precluding integration following mutation of the viral integrase enzyme. We describe efficient and simultaneously temporally controllable transfer and expression of the master transcription factor Oct4 using integration-deficient retroviral vectors and demonstrate that improved episomal expression, transgene performance and episomal kinetics make RET suitable to provide levels and expression profiles of Oct4 sufficient to achieve full reprogramming of human fibroblasts co-expressing the remaining reprogramming factors into iPSCs. Deciphering ways to improve RET-mediated transgene delivery and performance and with detailed kinetic analyses, our results provide the basis for a variety of applications requiring transient ectopic expression of transcription factors.
As a major advantage over currently available transient technologies, retroviral vectors allow for pseudotyping and thus access to a multitude of different cell types. 38 Beyond that, they are compatible with receptor-mediated entry strategies using antibody domains and equipment with modified measles virus envelope proteins, allowing targeting of specific cell types in vitro and in vivo. 39, 40 In contrast to plasmid-based approaches, viral delivery enables efficient targeting of primary cell types, which can be difficult to transfect or even refractory. Reported residual integration rates of RET vectors are similar to those observed with plasmids. However, especially for EBNA1/oriP-based systems, multiple passages are required for removal of all episomal sequences, 41 whereas our retroviral episomes were lost during the first passages of iPSC culture. Furthermore, although plasmid-based reprogramming only required a single application in many cases, additional transgenes such as the SV40 large T oncogene or knockdown of p53 were often included to supplement the canonical four reprogramming factors. 35 PluriTest results were plotted on the empirically defined density distribution for previously referenced PSCs (red cloud) and somatic cells (blue cloud). Samples were assessed in duplicates (repl. = replicate).
As transient viral delivery tools, adenoviral and Sendai virus (SeV) vector systems have been used. In contrast to RET, adenoviral vectors were not associated with residual integration in reprogramming, but showed very low efficiencies of 0.0002% 43 and 0.0006%, 44 respectively. We in our approaches reached efficiencies of 0.02% up to 3.5%. SeV systems offer the advantage of exclusively involving RNA intermediates, excluding potential residual integration, and of producing high reprogramming efficiencies of up to 1%. 45 Nevertheless, production of SeV particles is comparably complicated. Furthermore, initially used replication-competent systems resulted in long-term maintenance of vector copies and thus have been replaced by temperature-sensitive strains with reprogramming efficiencies of o0.02-0.1%. 45, 46 While expression height depends on the position of transgene insertion within the SeV vector genome, 47 a promoter of choice can be selected for retroviral vectors. Overall, considering the possibility to pseudotype retroviral vectors along with easy packaging of particles and high efficiency in transducing primary cells, RET appears as a promising alternative to current technologies and might be selected depending on the specific requirements of a given application.
Furthermore, integration-deficient retroviral vectors offer a great flexibility for vector design. Although LTR-driven integrating constructs should not be used for therapeutic applications in an integrated form, we identified this configuration to be superior for episomal Oct4 expression in comparison with GV and LV SIN vectors. Inclusion of a retroviral intron and a longer and reportedly stronger PRE in our LTR-driven constructs might have contributed to this effect. 24 However, the optimal vector architecture might be context dependent, as d2GFP expression (mean fluorescence intensity) from eGV SIN vectors was comparable to that from their LTR-driven counterparts at similar transduction levels.
Episomal expression in previous reports has been shown to be reduced per vector copy when compared with respective integrating counterparts. 5 We also observed lower Oct4 episomal expression in luciferase assays and in flow cytometric quantification of d2GFP transfer. However, we were able to improve episomal expression, allowing for the generation of hiPSCs, a setting known to require comparably high and prolonged transgene expression. 17 Further underlining the potency of our improvements is the fact that Oct4 probably is the most difficult reprogramming factor to be delivered by an episomal technique, as it optimally is required to be expressed in excess over the remaining factors to achieve efficient and full reprogramming. 48 The stimulation of episomal expression by HDACi has previously been reported both for eGV and eLV vectors, with the proposed mechanism being interference with episomal silencing. 25, 26 Supporting these considerations, we observed no effects of the HDACi VPA on transduction efficiencies or episomal copy numbers (data not shown), but expression levels were increased. In our reprogramming approach, addition of VPA might have exerted a dual function by also positively affecting the reprogramming process itself. Various HDACi have been reported to improve reprogramming efficiencies and kinetics as a consequence of promoting histone acetylation. 49 Reprogramming is thought to be facilitated by providing reprogramming factors better access to chromatin and by establishing a global gene expression state that renders the cells more poised toward reprogramming. 18 Following a similar principle, boosting of the performance of our model transcription factor Oct4 by fusion to HSV VP16 might also have acted in a dual manner by recruiting histone acetyltransferases and promoting global chromatin decondensation. 50 However, we only adopted the repetitive 13-amino-acid minimal motif of VP16's TAD, which is known to be highly potent in transactivation, 29, 30 but which might not recruit the entire repertoire of interaction partners of full-length VP16.
The benefit of using the strong transactivation potential of VP16 fused to reprogramming factors has previously been demonstrated, achieving a 78-fold higher colony yield when using modified Oct4. 51 Owing to the different readout systems and the use of a different motif from VP16's TAD, these results cannot be directly compared with our data. We observed a twofold increase in activity with Oct4-VP16 in luciferase assays. However, we cannot exclude that stronger effects would have been observed during reprogramming. As subtle differences in Oct4 expression levels can already influence cell fate decisions, such as maintaining or exiting the ES status, 19 reprogramming efficiency is potentially stimulated in more than a 1:1 manner. Arguing for a strong effect, we could only obtain hiPSC colonies with Oct4-VP16, whereas unmodified hOct4co did not generate hiPSCs (with an equal volume of supernatant).
In addition to reprogramming, Oct4 variants with increased activity might be beneficial in a number of further conversion settings. 52 Of interest here for our episomal transfer strategy are the trans-differentiation of fibroblasts into neural stem cells, 20, 21 multilineage blood precursors 22 and cardiomyocytes, 23 especially as only temporally restricted Oct4 pulses led to the generation of neural stem cells and cardiomyocytes.
A very important aspect of transient delivery modes involving DNA intermediates is the question of residual integration. For retroviral (mostly LV) episomes, integration frequencies have been reported to range from below 0.1 to 2.3%. 5 Analyses of integration characteristics with regard to vector-genome junctions suggest that these events are not mediated by the activity of viral integrase, but occur rather spontaneously owing to the activation of cellular DNA repair mechanisms, as commonly observed for transfected plasmids and other forms of foreign DNA. 53 Encouragingly, more than 50% of our hiPSC clones were free of residual Oct4 integrations. Although the rate of integration events is still higher than commonly reported episome integration frequencies, 5 it is surprisingly low given the high selective pressure during reprogramming and the generally rare number of reprogramming events. A similar phenomenon can also be observed for plasmid-based approaches, for which the commonly low residual integration rate increases markedly in the reprogramming context, ranging here from 18% to more than 90%. 42, [54] [55] [56] Importantly, in our setting, lowering the episomal vector dose or prolonging the intervals between individual rounds of episomal transduction diminished residual integration to o 15% and 10%, respectively, while still achieving complete reprogramming. This is in stark contrast to a previous reprogramming approach using eLV vectors where reprogramming was dependent on the residual integration of (at least) the large T antigen. 57 Generation of iPSCs completely based on RET might be challenging as it requires four different transcription factors expressed at high levels over a relatively long period of at least 8-10 days. 17 In the future, RET-based reprogramming might become possible by carefully selecting starting cell populations (e.g., epithelial cells can be reprogrammed with just two factors) 58 and by the extended use of chemical inhibitors facilitating reprogramming 49 to generate transgene-and vector-free iPSCs. The recent identification of Mbd3, a component of the NuRD repressor complex, as the predominant barrier to reprogramming 59 offers further options to apply RET in reprogramming. Reaching almost 100% reprogramming efficiency with stable OSKM expression in Mbd3 knockout cells, knockdown of Mbd3 could enable RET-based iPSC generation by transient expression of OKSM. Alternatively, the RET system could provide a platform for transient short hairpin RNA-based knockdown of Mbd3 to increase reprogramming efficiencies irrespectively of the strategy chosen for OKSM expression.
Altogether, processes involving only few transcription factors and showing fast kinetics supposedly constitute the ideal targets for RET in the context of cell fate conversion. Several conversions already described in the literature match these criteria, 11 such as the trans-differentiation of pre-B cells into macrophages 13 or the conversion of fibroblasts into muscle cells, 12 as well as directed differentiation approaches starting from ESCs or iPSCs.
As the RET system offers a high dynamic range both in terms of expression magnitude and duration, it can adjust to the particular requirements of a given application. Thereby, our findings with regard to vector architecture and boosting strategies can be transferred to any conversion process by simply exchanging the transgene. Fine-tuning of expression levels can furthermore be achieved by selecting a promoter of choice and by the amount of vector particles applied, that is, the number of episomal copies present per cell. Whereas RET has previously been used primarily to achieve stable gene transfer in quiescent tissues or very short-lived transfer to dividing cells, 5 our kinetic model shows that sequential transductions enable generation of intermediate-lived expression windows of predefinable duration, which might prove to be a big advantage for various applications.
In summary, we established and optimized a retroviral episomal transfer system mediating transient but sustained expression of transcription factors in a temporally adjustable manner, which readily allowed generation of human iPSCs without inducing chromosomal aberrations. We therefore provide proof-of-principle that our modified RET system is potent enough to achieve a biologic effect in the context of cell fate conversion, and can likely be transferred to a variety of further applications in biomedical research and therapy.
MATERIALS AND METHODS
Plasmids and vector design
Retroviral vector backbones (R = GV; L = LV) exhibited a modular design, starting with the 5'-LTR with (SIN) or without (LTR-driven) an SIN deletion of the U3 region, followed by an internal (SF = SFFV) promoter in case of SIN vectors, the transgene cassette and a PRE and terminated by the 3'-LTR. LTR-driven vectors used a longer PRE version (gPRE) than the SIN vectors (wPRE). Retroviral vectors were based on previously described backbones: LV SIN vectors were based on the RRL.PPT.SF backbone, 60 GV SIN vectors were derived from the SRS11.SF backbone 61 and GV LTR-driven vectors exhibited the RSF91 backbone design. 61 Polycistronic transgene cassettes contained co-expression modules separated by heterologous 2A sites, and, in some cases, a fluorescent marker co-expressed by an IRES. Transgene cassettes subject to this study included hOct4co, hOct4co fused to a threefold repeat of a minimal motif of HSV VP16 (Oct4-VP16), hOct4co fused to eGFP, hOct4co plus codon-optimized human Klf4 (OK), hKlf4co plus codon-optimized human Sox2 and wild-type human c-Myc followed by an IRES and dTomato (KSM) and a 4-in-1 reprogramming cassette built up by hOct4co followed by KSM.idTom (OKSM). An Oct4 luciferase reporter plasmid, pGL4.10-TRE-Oct4 (TRE = transcription factor response element), was generated based on the firefly luciferase (luc2) encoding plasmid pGL4.10 (Promega, Mannheim, Germany) by insertion of an Oct4 response unit consisting of a direct sixfold repeat of an hOct4 TRE coupled to a minimal promoter upstream of the luciferase gene. To generate a stable Oct4 luciferase reporter cell line, a reporter vector (SRS11-TRE-Oct4) was constructed based on the GV SIN backbone 'SRS11' encoding in antisense the Oct4 reporter cassette from pGL4.10-TRE-Oct4. The vector backbone of SRS11-TRE-Oct4 was derived from a bidirectional construct (pRBid.nC.GFP. PGK.mCherry*). 62 Cloning details are available upon request.
Cell culture
The 293T, 293T Oct4 luciferase reporter, SC-1 and HeLa P1 cells were cultured in Dulbecco's modified Eagle's medium (Biochrom, Berlin, Germany) supplemented with 10% heat-inactivated fetal bovine serum, 100 U ml − 1 penicillin, 100 μg ml − 1 streptomycin and 1 mM sodium pyruvate (all PAA Laboratories GmbH, Coelbe, Germany). C3H murine embryonic fibroblasts (MEFs) and NuFFs were grown in MEF medium consisting of Dulbecco's modified Eagle's medium (low glucose) supplemented with 10-15% heat-inactivated fetal bovine serum, 100 U ml − 1 penicillin, 100 μg ml − 1 streptomycin, 2 mM L-glutamine (all PAA), 1% MEM nonessential amino acids solution (Gibco, Karlsruhe, Germany) and 100 μM β-mercaptoethanol (Sigma-Aldrich GmbH, Seelze, Germany). hiPSCs were kept on γ-irradiated C3H MEFs in hiPSC medium consisting of Dulbecco's modified Eagle's medium/F12 GlutaMAX with 20% knockout serum replacement (both Gibco), 100 U ml − 1 penicillin, 100 μg ml − 1 streptomycin, 2 mM L-glutamine (all PAA), 1% MEM nonessential amino acids solution (Gibco), 100 μM β-mercaptoethanol (Sigma-Aldrich) and 40 ng ml − 1 basic fibroblast growth factor or, alternatively, on Matrigel Basement Membrane Matrix (Becton Dickinson, Heidelberg, Germany) using conditioned hiPSC medium. For conditioned medium, hiPSC medium was incubated for 24 h on γ-irradiated C3H MEFs, harvested, filtered and supplemented with fresh basic fibroblast growth factor (40 ng ml − 1 ).
Production of viral vector particles
Generation of viral supernatants was performed as described previously 60 by transient transfection of 293T cells in the presence of 15 mM HEPES (PAA) and 25 μM chloroquine (Sigma-Aldrich) following calcium phosphate precipitation. Cells were seeded in 10 cm dishes at a density of 5 × 10 6 the day before transfection. For GV vectors, 5 μg of the vector were transfected along with 6 μg murine leukemia virus gag/pol expression plasmid (for integrating vector preparations) or integration-defective murine leukemia virus gag/pol (D184A) 62 (for episomal preparations) and 1.5 μg of vesicular stomatitis virus envelope glycoprotein (VSVg) encoding plasmid (pMD.G). For LV production, 5 μg of the vector were co-transfected with expression plasmids for Rev (6 μg), LV gag/pol (for integration-proficient vector preparations) or integration-deficient LV gag/pol (D64V) (for episomal preparations) (12 μg) and VSVg (1.5 μg). To monitor transfection efficiency for vectors lacking fluorescent reporters, 0.5 μg of pCMV.dsRed.Express (BD Clontech GmbH, Heidelberg, Germany) were additionally included. Supernatants were collected 36 and 48 h after transfection, filtered, pooled, optionally concentrated via ultracentrifugation for 2 h at 25 000 r.p.m. (rotor SW28 or SW32Ti; Beckman Coulter GmbH, Krefeld, Germany) and 4°C, and stored at − 80°C.
Transduction of cells with viral vector preparations
Cells were seeded in 12-well plates the day before transduction. The medium was changed to 500 μl culture medium supplemented with 4 μg ml − 1 protamine sulfate (Sigma-Aldrich), viral supernatants were added and spin inoculated for 1 h at 2000 r.p.m. and 32-37°C. At 6-14 h after transduction, the medium was either changed to normal culture medium or 1-2 ml of fresh culture medium was added to the transduction volume.
Titration of viral vector preparations
For vector preparations not encoding fluorescent proteins, 293T cells were seeded at 2.5 × 10 5 cells per well of a 12-well dish and transduced the following day. Cells were harvested with trypsin 30-36 h after transduction, pelleted and stored at − 20°C. Genomic DNA and episomes were extracted and copy numbers determined based on quantitative PCR analysis. For titration of episomal or integrating vector preparations encoding fluorescent reporter proteins, 293T, SC-1 or NuFF cells were transduced with the vector preparations and analyzed by flow cytometry 30-36 h after transduction for episomal preparations and 3-4 days after transduction for integrating preparations.
Luciferase reporter assay
For transient dual-luciferase assays, 1 × 10 5 HeLa P1 cells were seeded in 12-well plates and transfected the following day with 0.5 μg of a 40:1 mix of pGL4.10-TRE-Oct4 and pGL4.74-hRluc (Promega) using polyethylenimine (Polysciences Europe GmbH, Eppelheim, Germany) transfection. The next day, cells were split, pooled and replated. Cells were transduced the following day with viral supernatants and subjected to analysis 24-48 h after transduction according to the manufacturer's protocol (DualLuciferase Reporter Assay System; Promega), but using 15 μl of cell lysate and 40 μl of each LARII and Stop&Glo Buffer in a 2 s measurement in a Lumat LB 9507 tube luminometer (Berthold Technologies, Bad Wildbad, Germany). Reporter-transfected, but non-transduced, samples were used to determine background activation levels. Firefly counts were divided by Renilla counts for normalization and then divided by background levels to present relative activation levels.
For luciferase assays based on a stable 293T Oct4 reporter cell line, 2.5 × 10 5 cells were plated per well of a 12-well-plate and transduced with viral supernatants the following day. Samples were harvested at the indicated time points and stored at − 20°C until analysis. Measurement of luciferase activity was performed as previously described using 10 μl of cell lysate per sample in a 2 s measurement reaction. 63 Firefly luciferase counts were normalized to the total protein content of each lysate quantified by standard Bradford assay (Bio-Rad Laboratories GmbH, München, Germany) performed on a 96-well plate reader and analyzed with SoftMax Pro 4.0 software (Molecular Devices, Sunnyvale, CA, USA).
Reprogramming
The medium was changed daily throughout the entire reprogramming process. NuFF cells were seeded on 12-well dishes at 1 × 10 4 cells per well. The following day, cells were transduced with VSVg-pseudotyped integrating LV vectors encoding either OKSM (RRL.PPT.SF.hOKSM.idTom. pre) or KSM (RRL.PPT.SF.hKSM.idTom.pre) at a multiplicity of infection of 10 or 20 (Reprogramming 1; titrated on SC-1 cells) or multiplicity of infection of 20 (Reprogramming 2; titrated on NuFF cells) in MEF medium in the presence of 4 μg ml − 1 protamine sulfate and 50 μg ml − 1 2-phospho-L-ascorbic acid (P-Vit.C) 64 (Sigma-Alrich). The following day, cells transduced with integrating KSM vector were transduced with VSVgpseudotyped, GV, episomal or integrating supernatants of RSF91.Oct4-VP16.pre at low (Reprogramming 2) or high viral dose (Reprogrammings 1 and 2) for episomal supernatants. Transduction occurred via spin inoculation in MEF medium supplemented with protamine sulfate (PS), P-Vit.C and 2 mM VPA (Ergenyl; Sanofi-Aventis, Frankfurt, Germany). Directly after centrifugation, another 500 μl of MEF medium (plus PS, P-Vit.C, VPA) was added to each well. For episomal supernatants, this procedure was repeated every 24 h for another 12 days. The medium was changed to ½ MEF and ½ hiPSC (plus P-Vit.C and VPA) on day 6 and to full hiPSC (plus P-Vit.C and VPA) on day 8 after the initial transduction for all samples. Reprogramming 1: Cells were split on day 8 and grown until the emergence of iPSC-like colonies. VPA was added to the medium up to and including day 18. Reprogramming 2: On day 7, each sample was split on two wells in a 12-well dish and one feeder-coated well in a 6-well dish. Cells on 12-well dishes were subjected to further transduction, whereas cells in 6-well dishes were not transduced again. On day 14, transduction was complete and one of each replicate from the 12-well dishes was split to a feeder-coated 6-well dish. On day 17, the medium was changed to hiPSC medium without P-Vit.C and VPA and changed back to supplement with P-Vit.C and VPA on day 21. On day 27, the medium was changed to hiPSC medium supplemented with P-Vit.C, but without VPA. From day 53 on, cells were cultured in hiPSC medium without any supplement. The first episomal hiPSC-like colonies in both experiments were harvested around days 27-30. hiPSCs were kept on feeder-coated dishes in hiPSC medium and passaged by manual picking in the presence of 10 μM ROCK (Rho-associated coiled coil-forming protein serine/threonine kinase) inhibitor Y-27632.
Determination of reprogramming efficiency
The number of generated hiPSC colonies for each individual condition derived from the same primary well was divided by the cell number initially plated for reprogramming. When taking into account splitting of primary wells during reprogramming, values for each individual condition were additionally multiplied with the split ratio. As initial colonies were picked at multiple time points, we cannot exclude that individual colonies were picked and thus counted more than once.
Statistics
Data are expressed as mean ± s.d. Statistical analysis was performed based on the unpaired t-test or, in case of significantly different variances, applying the nonparametric Mann-Whitney test (as indicated).
